|
CN106868025A
|
|
The method that tripolymer Ebola virus glycoproteins mutant is prepared with yeast
|
|
CN106692963A
|
|
Combined vaccine for preventing staphylococcus aureus infection and tetanus
|
|
CN106637422A
|
|
Method for constructing Hi-C high-throughput sequencing library
|
|
CN106519033A
|
|
Anti-uPAR (urokinase plasminogen activator receptor)-antigen humanized antibody H2DL2 and application thereof
|
|
CN106350527A
|
|
Diphtheria toxin mutant with characteristic of soluble high expression in Escherichia coli
|
|
CN106544345A
|
|
Promoter 5M6A and its application
|
|
CN106148302A
|
|
A kind of method for purifying recombinant proteins
|
|
CN106084026A
|
|
Tumor vascular endothelial cell mark 8 mutant, its fusion protein and application
|
|
CN105969711A
|
|
Recombinant attenuated Bacillus anthracis and application thereof
|
|
CN105820218A
|
|
Protein CAA' for preventing and treating radiation damage and application thereof
|
|
CN105483140A
|
|
Ebola virus disease vaccine taking human replication deficient adenovirus as vector
|
|
CN105542004A
|
|
Neutralizing monoclonal antibody resisting to tetanus toxin and application thereof
|
|
CN106589122A
|
|
Humanized anti-human subtype interferon alpha antibody and its application
|
|
CN106511994A
|
|
Carrier protein of bacterial polysaccharide conjugate vaccine and application thereof
|
|
CN106191054A
|
|
Promoter 3M1F and application thereof
|
|
CN106191052A
|
|
Promoter 17M11D and application thereof
|
|
CN106191053A
|
|
Promoter recea4 and application thereof
|
|
CN106191051A
|
|
Promoter 7M4D and application thereof
|
|
CN106191050A
|
|
Promoter 6M3B and application thereof
|
|
CN106191049A
|
|
Promoter 32M6A and application thereof
|
